MannKind Corporation
Use of Ultrarapid Acting Insulin
Last updated:
Abstract:
Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
Status:
Application
Type:
Utility
Filling date:
26 Apr 2021
Issue date:
12 Aug 2021